Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | SLC5A7 | Q9GZV3 | 4/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2554645 | 0.87 | GPR119 (0.44) | GPR119SLC5A7HRH3CYP2D6 | |
| SCHEMBL2556367 | 0.86 | GPR119 (0.45) | GPR119HRH3 | |
| SCHEMBL14634535 | 0.86 | GPR119 (0.45) | GPR119HRH3 | |
| SCHEMBL2556292 | 0.82 | HRH3 (0.52) | GPR119SLC5A7HRH3 | |
| SCHEMBL12282975 | 0.81 | GPR119 (0.73) | GPR119 | |
| SCHEMBL2553366 | 0.81 | GPR119 (0.73) | GPR119 | |
| SCHEMBL2554700 | 0.79 | GPR119 (0.57) | GPR119SLC5A7HRH3CYP1A2 | |
| SCHEMBL2551264 | 0.79 | GPR119 (0.57) | GPR119SLC5A7HRH3CYP1A2CYP2D6 | |
| SCHEMBL14634499 | 0.79 | IKBKB (0.43) | GPR119 | |
| SCHEMBL14634498 | 0.79 | IKBKB (0.43) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2556056-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011127051-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | WO | disclosed |